However, in a preclinical study[37], the combination of IL-1β blocker with other anti-CD3 monoclonal antibody resulted in significantly greater clinical remission of diabetes suggesting that this combination might be more suitable in new onset type 1 diabetes or in prevention trials in individuals with pre-type 1 diabetes. This evidence concerns the gene IL1B and type 1 diabetes mellitus.